Cochrane Review Group
Infectious Diseases
135 systematic reviews in Infectious Diseases ask 1,518 questions. 8.9% have no studies to answer them, 23.1% rest on very low certainty evidence and 30.5% reach moderate or high certainty.
Reviews
135
Questions
1,518
current versions
No studies
8.9%
Moderate or high
30.5%
No studies 135 · 8.9%Ungraded 150 · 9.9%Very low 350 · 23.1%Low 420 · 27.7%Moderate 321 · 21.1%High 142 · 9.4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Thinnest evidence
All no studies and very low questions| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Favipiravir vs no treatment, supportive treatment, or other antiviral treatment All‐cause mortality – at 28 to 30 days, or in‐hospital · people with confirmed COVID‐19 Favipiravir for treating COVID‐19 (2024) · Cochrane | RR 0.84 [0.49, 1.46] | 11 studies · 3459 participants | Very low |
Favipiravir vs no treatment, supportive treatment, or other antiviral treatment Progression to invasive mechanical ventilation · people with confirmed COVID‐19 Favipiravir for treating COVID‐19 (2024) · Cochrane | RR 0.86 [0.68, 1.09] | 8 studies · 1383 participants | Very low |
Favipiravir vs no treatment, supportive treatment, or other antiviral treatment Time to clinical improvement (defined as time to a 2‐point reduction in patients’ admission status on WHO’s ordinal scale) · people with confirmed COVID‐19 Favipiravir for treating COVID‐19 (2024) · Cochrane | HR 1.13 [0.69, 1.83] | 4 studies · 721 participants | Very low |
wMel‐Wolbachia infected Aedes aegypti deployments vs no deployments Virologically confirmed dengue case incidence (any severity, any phenotype) · children and adults at risk of dengue infection Wolbachia ‐carrying Aedes mosquitoes for preventing dengue infection (2024) · Cochrane | no estimate extracted | NR | No studies |
wMel‐Wolbachia infected Aedes aegypti deployments vs no deployments Prevalence of dengue RNA in the mosquito population · children and adults at risk of dengue infection Wolbachia ‐carrying Aedes mosquitoes for preventing dengue infection (2024) · Cochrane | no estimate extracted | NR | No studies |
wMel‐Wolbachia infected Aedes aegypti deployments vs no deployments Mosquito density (for population suppression strategy) · children and adults at risk of dengue infection Wolbachia ‐carrying Aedes mosquitoes for preventing dengue infection (2024) · Cochrane | no estimate extracted | NR | No studies |
wMel‐Wolbachia infected Aedes aegypti deployments vs no deployments Prevalence of Wolbachia‐carrying mosquitoes (for population replacement strategy) · children and adults at risk of dengue infection Wolbachia ‐carrying Aedes mosquitoes for preventing dengue infection (2024) · Cochrane | no estimate extracted | NR | No studies |
wMel‐Wolbachia infected Aedes aegypti deployments vs no deployments Adverse events potentially related to Wolbachia‐carrying Aedes deployments · children and adults at risk of dengue infection Wolbachia ‐carrying Aedes mosquitoes for preventing dengue infection (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Cluster‐RCTs · adults and children Interventions to improve sanitation for preventing diarrhoea (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Cluster‐RCTs · adults and children Interventions to improve sanitation for preventing diarrhoea (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR NRCTs · adults and children Interventions to improve sanitation for preventing diarrhoea (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Cluster‐RCTs · adults and children Interventions to improve sanitation for preventing diarrhoea (2023) · Cochrane | no estimate extracted | NR | No studies |
Reviews 135
Oral killed cholera vaccines for preventing cholera
CochraneSoF table
8 questions
Favipiravir for treating COVID‐19
CochraneSoF table
7 questions
Wolbachia ‐carrying Aedes mosquitoes for preventing dengue infection
CochraneSoF table
6 questions
Interventions to improve sanitation for preventing diarrhoea
CochraneSoF table
16 questions
Balanced crystalloid solutions versus 0.9% saline for treating acute diarrhoea and severe dehydration in children
CochraneSoF table
8 questions
Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19
CochraneSoF table
22 questions
Topical repellents for malaria prevention
CochraneSoF table
5 questions
Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria
CochraneSoF table
32 questions
Mosquito aquatic habitat modification and manipulation interventions to control malaria
CochraneSoF table
13 questions
Adding rapid diagnostic tests to community‐based programmes for treating malaria
CochraneSoF table
7 questions
Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins
CochraneSoF table
21 questions
Symptom‐ and chest‐radiography screening for active pulmonary tuberculosis in HIV‐negative adults and adults with unknown HIV status
CochraneSoF table
25 questions
Interventions to improve water, sanitation, and hygiene for preventing soil‐transmitted helminth infection
CochraneSoF table
6 questions
Indoor residual spraying for preventing malaria in communities using insecticide‐treated nets
CochraneSoF table
8 questions
Accuracy of measures for antiretroviral adherence in people living with HIV
CochraneSoF table
6 questions
Xpert MTB/RIF Ultra assay for tuberculosis disease and rifampicin resistance in children
CochraneSoF table
7 questions
House modifications for preventing malaria
CochraneSoF table
4 questions
Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin
CochraneSoF table
25 questions
Ivermectin for preventing and treating COVID‐19
CochraneSoF table
16 questions
Anthelmintics for people with neurocysticercosis
CochraneSoF table
5 questions
Hand‐washing promotion for preventing diarrhoea
CochraneSoF table
4 questions
Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria
CochraneSoF table
13 questions
Vaccines for preventing rotavirus diarrhoea: vaccines in use
CochraneSoF table
56 questions
Mass drug administration for malaria
CochraneSoF table
19 questions
Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis
CochraneSoF table
10 questions